BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15471949)

  • 1. Heparanase promotes the spontaneous metastasis of myeloma cells to bone.
    Yang Y; Macleod V; Bendre M; Huang Y; Theus AM; Miao HQ; Kussie P; Yaccoby S; Epstein J; Suva LJ; Kelly T; Sanderson RD
    Blood; 2005 Feb; 105(3):1303-9. PubMed ID: 15471949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis.
    Yang Y; Macleod V; Miao HQ; Theus A; Zhan F; Shaughnessy JD; Sawyer J; Li JP; Zcharia E; Vlodavsky I; Sanderson RD
    J Biol Chem; 2007 May; 282(18):13326-33. PubMed ID: 17347152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.
    Yang Y; Ren Y; Ramani VC; Nan L; Suva LJ; Sanderson RD
    Cancer Res; 2010 Nov; 70(21):8329-38. PubMed ID: 20978204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.
    Kelly T; Suva LJ; Huang Y; Macleod V; Miao HQ; Walker RC; Sanderson RD
    Cancer Res; 2005 Jul; 65(13):5778-84. PubMed ID: 15994953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.
    Barash U; Cohen-Kaplan V; Dowek I; Sanderson RD; Ilan N; Vlodavsky I
    FEBS J; 2010 Oct; 277(19):3890-903. PubMed ID: 20840586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
    Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
    Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of host heparanase in promoting tumor growth and metastasis.
    Zhang GL; Gutter-Kapon L; Ilan N; Batool T; Singh K; Digre A; Luo Z; Sandler S; Shaked Y; Sanderson RD; Wang XM; Li JP; Vlodavsky I
    Matrix Biol; 2020 Nov; 93():25-42. PubMed ID: 32534153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity.
    Ramani VC; Yang Y; Ren Y; Nan L; Sanderson RD
    J Biol Chem; 2011 Feb; 286(8):6490-9. PubMed ID: 21131364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparanase: A Dynamic Promoter of Myeloma Progression.
    Purushothaman A; Sanderson RD
    Adv Exp Med Biol; 2020; 1221():331-349. PubMed ID: 32274716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparanase promotes myeloma stemness and in vivo tumorigenesis.
    Tripathi K; Ramani VC; Bandari SK; Amin R; Brown EE; Ritchie JP; Stewart MD; Sanderson RD
    Matrix Biol; 2020 Jun; 88():53-68. PubMed ID: 31812535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
    Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
    Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis.
    Sanderson RD; Yang Y; Suva LJ; Kelly T
    Matrix Biol; 2004 Oct; 23(6):341-52. PubMed ID: 15533755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.
    Purushothaman A; Chen L; Yang Y; Sanderson RD
    J Biol Chem; 2008 Nov; 283(47):32628-36. PubMed ID: 18812315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor Function.
    Amin R; Tripathi K; Sanderson RD
    Cells; 2020 Sep; 9(9):. PubMed ID: 32899927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.
    Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD
    Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.
    Weissmann M; Arvatz G; Horowitz N; Feld S; Naroditsky I; Zhang Y; Ng M; Hammond E; Nevo E; Vlodavsky I; Ilan N
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):704-9. PubMed ID: 26729870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
    Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
    J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Function of heparanase in prostate tumorigenesis: potential for therapy.
    Lerner I; Baraz L; Pikarsky E; Meirovitz A; Edovitsky E; Peretz T; Vlodavsky I; Elkin M
    Clin Cancer Res; 2008 Feb; 14(3):668-76. PubMed ID: 18212251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.
    Li J; Pan Q; Rowan PD; Trotter TN; Peker D; Regal KM; Javed A; Suva LJ; Yang Y
    Oncotarget; 2016 Mar; 7(10):11299-309. PubMed ID: 26849235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.